Detaljer på forslag

Biologisk vurdering af medicinsk udstyr – Del 17: Toksikologisk risikovurdering af bestanddele i medicinsk udstyr – Tillæg 1
Forslagstitel på sprog (en): Biological evaluation of medical devices – Part 17: Toxicological risk assessment of medical device constituents – Amendment 1 (ISO 10993-17:2023/DAmd 1:2024)
Nummer:DSF/EN ISO 10993-17:2023/prA1
Type:Forslag
Kilde:CEN
Udvalg:S-258
Udvalgsnavn:Bioforligelighed og klinisk dokumentation
Forslag udgivet:29. aug 2024
Kommentarfrist:9. okt 2024
Antal kommentarer:0
Læs forslag
Committee Home Page
Tip en kollega
Beskrivelse af forslaget:This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1. The process described in this document applies to chemical characterization information obtained in line with ISO 10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable. The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as: –    constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO 10993-18:2020, Annex E and ISO/TS 21726); –    a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO 10993-18:2020, Annex C). The process described in this document is also not applicable to: –    medical device constituents that do not contact the body (e.g. in vitro diagnostics); –    biological risks associated with physical interactions of the medical device with the body (i.e. application of mechanical forces, energy or surface morphology, etc.), provided that the chemical exposure is not changed; –    active pharmaceutical ingredients of device-drug combination products or biologic components of device-biologic combination products as additional regulatory considerations can apply; –    exposure to a particular constituent that arises from sources other than the device, such as food, water or air.

Du kan kommentere på alle dele af dette dokument. Forslag vises i ét af to formater:

PDF-version
HTML-version

Hvis du ser indholdsfortegnelsen i venstre side, er det HTML-formatet. For at kommentere skal du åbne de enkelte afsnit ved at klikke på afsnittet i indholdsfortegnelsen.

Hvis du i stedet bliver bedt om at downloade et dokument, er det PDF-formatet. Du skal åbne dokumentet i et separat vindue og derefter kommentere ved at angive afsnitsnummer eller -tekst i "Sektion". Der er mere vejledning, når du har klikket på "Læs forslag".

For at afsende kommentar til Dansk Standard, skal du klikke på "Send kommentar" for det aktuelle afsnit.. Hvis du ønsker at arbejde videre med dine kommentarer, skal du i stedet klikke på "Gem kommentar til senere redigering".

Du kan tilføje og ændre i gemte kommentarer, men hvis du sender kommentaren, kan du ikke vende tilbage for at redigere.

Hvis du har gemte kommentarer, som ikke er afsendt, vil du, før høringsperioden udløber, blive mindet om, at du har ikke-afsendte kommentarer.